Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in PIK3CA-Mutated Endometrial Carcinoma
NCT02728258Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Sep 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in endometrial carcinoma, sponsored by NRG Oncology. Started Sep 2016; status: completed.
02
Drugs
copanlisib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT02728258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728258.